



(51) International Patent Classification:

A61N 1/08 (2006.01) A61N 1/20 (2006.01)
A61N 1/18 (2006.01) A61N 1/36 (2006.01)

(21) International Application Number:

PCT/US2019/025707

(22) International Filing Date:

04 April 2019 (04.04.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/655,122 09 April 2018 (09.04.2018) US

(71) Applicant: **NEUROS MEDICAL, INC.** [US/US]; 35010 Chardon Road, #210, Willoughby Hills, OH 44094 (US).

(72) Inventors: **SYED SHAH, Nemath**; 35010 Chardon Road, #210, Willoughby Hills, OH 44094 (US). **FANG, Zi-Ping**; 35010 Chardon Road, #210, Willoughby Hills, OH 44094 (US).

(74) Agent: **SHOOP, Richard, D.** et al.; Shay Glenn LLP, 2755 Campus Drive, Suite 210, San Mateo, CA 94403 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: APPARATUSES AND METHODS FOR SETTING AN ELECTRICAL DOSE

(57) Abstract: Methods and apparatuses for setting a therapeutic dose of a neuromodulator implanted into a patient are described. The therapeutic dose typically includes a therapeutic dose duration including a ramp-up time to reach a peak modulation voltage and a sustained peak modulation time during which the voltage is sustained at the peak modulation voltage. The methods and apparatuses described herein may use a testing ramp to identify a peak modulation voltage that is patient-specific and provides a maximized therapeutic effect while remaining comfortably tolerable by the patient during the application of energy by the neuromodulator.




FIG. 2



APPARATUSES AND METHODS FOR SETTING AN ELECTRICAL DOSE**CROSS REFERENCE TO RELATED APPLICATIONS**

5 [0001] This patent claims priority to U.S. provisional patent application no. 62/655,122, titled (“APPARATUSES AND METHODS FOR SETTING AN ELECTRICAL DOSE”) filed on 09 April 2018.

[0002] This patent may be related to one or more of: U.S. patent application no. 15/510,824, titled “NERVE CUFF ELECTRODE FOR NEUROMODULATION IN LARGE HUMAN NERVE TRUNKS” and filed on September 12, 2014, which claims priority to U.S. patent 10 application Ser. No. 14/276,200 (now US 8,983,612) filed May 13, 2014; which is a continuation of U.S. patent application Ser. No. 13/474,926 filed May 18, 2012 now U.S. Pat. No. 8,731,676; which claims priority to U.S. patent application Ser. No. 61/487,877 filed May 19, 2011, each of which is expressly incorporated by reference herein in its entirety.

15 **INCORPORATION BY REFERENCE**

[0003] All publications and patent applications mentioned in this specification are herein incorporated by reference in their entirety to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

20 **FIELD**

[0004] The inventions described herein relate to the field of implantable neuromodulators.

BACKGROUND

25 [0005] Implantable neuromodulators (e.g., implantable neurostimulators) are increasingly used to treat pain and other indications, in many cases by the direct application of electrical energy to one or more nerves, including nerve bundles. Such electrical modulation may be used to excite or inhibit nerves, or both. An implantable neuromodulator may be implanted on, around or adjacent to a patient’s nerve or nerves for the delivery of electrical energy.

30 [0006] For example, electrical modulation may be applied to a nerve to treat the unwanted and/or uncoordinated generation of nerve impulses which may otherwise be a disabling factor in some medical conditions. Uncoordinated motor signals may produce spasticity in stroke, cerebral palsy, multiple sclerosis, and other conditions and may lead to pain, including pain resulting from amputation. The uncoordinated signals may result in the inability to make desired

functional movements. Involuntary motor signals in conditions including tics, choreas, and so on, may produce unwanted movements. Unwanted sensory signals can cause pain.

[0007] Electrical modulation to treat a patient is generally sensitive to the amount, during and intensity of the applied energy. For example, one non-limiting type of electrical therapy is
5 applying high-frequency alternating current (HFAC) to nerves that has been shown to block nerve activity, e.g., in the treatment of pain. An appropriate dose (e.g., the amount of electrical energy applied to the patient for effective treatment) may be set so that it causes the desired effect, such as inhibition of nerve activity to reduce pain. On the other hand, an inappropriate dosing may lead to no effect or possibly to irritation of the nerve.

10 [0008] Unfortunately, determining proper dosing for a patient may be time-intensive, and complicated. Further, the optimal dosing to treat a patient may be highly variable between patients, and indeed, even over time in the same patient. Thus, it would be beneficial to provide a method and/or apparatus for simplifying and reliably setting patient dosing. Described herein are methods and apparatuses that may address these needs.

15

SUMMARY OF THE DISCLOSURE

[0009] Described herein are methods and apparatuses (devices, systems, etc., including neuromodulators and systems including them) for setting the therapeutic dosing of a neuromodulator that is implanted into a patient. A therapy dose typically includes a therapeutic
20 dose duration including a therapy ramp-up time to reach a peak modulation voltage and a sustained peak modulation time during which the voltage is sustained at the peak modulation voltage. The setting processes described herein may adjust (e.g., set) the peak voltage of ramp to a voltage that is beyond the patient's nerve activation level and within a nerve blocking level. The dose parameters may also include the waveform parameters applied, e.g., pulsatile or
25 repeating (e.g., sinusoidal, square wave, saw-tooth, biphasic, etc.), and the frequency of the applied waveform (e.g., the high-frequency component). Other dose parameters may include the initial (e.g., starting) voltage, which may be, e.g., zero, or may be a minimum patient-detectable modulation voltage that is determined as described herein. In some variations, the therapeutic dose includes at least two parts; an initial ramp-up portion in which the voltage increases from the
30 initial voltage up to a peak modulation voltage, and a plateau portion, referred to as a sustained peak modulation time, during which the voltage is sustained at the peak modulation voltage. The duration of the ramp-up portion may be referred to as the ramp-up time. The duration of the second portion may be referred to as the plateau time. In some variations, these two portions may repeat and/or alternate.

[00010] The methods and apparatuses described herein may use a testing ramp applied by the implanted neuromodulator to identify a peak modulation voltage that is patient-specific and provides that patient with a maximal therapeutic effect while remaining comfortably tolerable by the patient during the application of energy by the neuromodulator. The testing ramp may be applied as part of a therapy dose-setting procedure during which a ramped voltage, having the same or a similar frequency as the therapeutic dose will have, is applied by the implanted neuromodulator. Feedback, either direct (such as patient reporting) or indirect (e.g., from patient biometrics) or both may be used to select the target sensation intensity modulation voltage. The target sensation intensity modulation voltage identified during the testing ramp application may be used, along with the intended therapeutic ramp-up time to determine the therapeutic dose peak modulation voltage. Thus, the methods and apparatuses described herein may, using a single test including a ramp-up in voltage intensity, determine an optimal dosage.

[00011] In the absence of the teachings described herein, it is difficult to determine an optimal dosage at which the applied voltage is increase to a peak and sustained for sufficiently long to achieve a therapeutic benefit. The inventors have found that although it is generally beneficial to apply as high a voltage as possible to the patient, particularly (but not exclusively) in applications in which neural modulation comprises high-frequency (e.g., greater than 1 kHz) modulation from an implanted neuromodulator to inhibit activity of a nerve or nerve bundle, there is a difficulty to define voltage threshold, above which further voltage amplitude may result in pain and/or discomfort for the patient. This threshold is not only variable between different patients, but may vary with respect to the individual patient. For example, patient sensitivity appears to depend at least slightly on the rate of increase of the voltage. Slower ramp-up times may generally permit a higher final voltage. However, inventors have also found that it is beneficial to maintain the therapeutic modulation such that a longer time is spent at the maximum voltages (e.g., the sustained or plateau period). Surprisingly, the inventors have found that it is possible to use a target sensation intensity modulation voltage that is specific to the patient from the test voltage ramp and scale this target sensation intensity modulation voltage for other ramps, which may allow for the use of a single setting (e.g., therapy dose-setting) procedure to determine the target sensation intensity modulation voltage from a known ramp-up to be used to determine a therapeutic peak modulation voltage, as described in detail herein.

[00012] Note that the target sensation intensity modulation voltage may be the voltage that induces a target intensity of sensation in the patient during the test. More specifically, this target sensation intensity modulation voltage may be the maximum voltage that the patient can tolerate for the therapy period.

[00013] In any of the methods described herein, the testing may be performed on a patient after a period of inactivity (non-modulation) of the neuromodulator device. For example, there may be a recovery period during which the maximum voltage to induce the target intensity of sensation may change, and be unreliable. Thus, the method may have a delay period before
5 applying the test ramp. This delay may be 1 minute or more, 5 minutes or more, 10 minutes or more, 15 minutes or more, 20 minutes or more, 25 minutes or more, 30 minutes or more, 35 minutes or more, 40 minutes or more, 1 hour or more, etc. The testing period may itself be brief (e.g., one or more trials of 30 min or less, which may be separated by this delay period).

[00014] In general these methods may be applied to, but are not limited to, the use with
10 neuromodulation to provide a high-frequency block of a nerve or bundle of nerves. For example, these methods and apparatuses may be used to set and/or optimize therapy treatment dosing for a high-frequency block of a nerve such as the sciatic nerve, dorsal root ganglion (DRG), etc.

[00015] For example, described herein are methods of setting a therapeutic dose of a neuromodulator implanted into a patient, wherein the therapeutic dose comprises a therapeutic
15 dose duration including a therapy ramp-up time to reach a peak modulation voltage and a sustained peak modulation time during which the voltage is sustained at the peak modulation voltage. The method may include: applying a test voltage ramp from the neuromodulator implanted into the patient; determining a target sensation intensity modulation voltage that is specific to the patient from the test voltage ramp; estimating the peak modulation voltage as a
20 function of the target sensation intensity modulation voltage and the therapy ramp-up time to reach the peak modulation voltage; and setting the therapeutic dose using the estimated peak modulation voltage.

[00016] The target sensation intensity modulation voltage may be a maximum patient-tolerable modulation voltage.

[00017] In general, the therapy ramp-up time may be any appropriate portion of the
25 therapeutic dose duration, such as between about 10% and about 90% (e.g., between about 30% and about 70%, between about 40% and about 60%, between about 45% and about 55%, about 50%, etc.). For example, the therapy ramp-up time to the peak modulation voltage may be set to be half of the therapeutic dose duration. The balance of the therapeutic dose duration may be the
30 plateau period (e.g., the sustained peak modulation time). As mentioned, above, in some variations, the therapeutic dose may then repeat, either immediately or more preferably after a "lockout" period during which modulation is not applied by the neuromodulator. The lockout period may be 5 minutes or more (e.g., 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes, 40 minutes, 45 minutes, 50 minutes, 55 minutes, 60 minutes,
35 etc.).

[00018] The therapeutic dose duration may be any appropriate length of time, e.g., between about 5 minutes and about 2 hours, e.g., between about 10 minutes and 1 hours, between about 15 minutes and 50 minutes, between about 20 minutes and 45 minutes, between about 25 minutes and about 40 minutes, etc., such as about 30 minutes.

5 [00019] Determining the target sensation intensity modulation voltage may include determining the voltage of the test voltage ramp being applied when a patient-reported feedback indicating the strongest sensation that the patient can tolerate for a therapeutic dose is received during the application of the test voltage ramp. During the application of the voltage ramp, for example, the patient may self-report on the experienced sensation from the applied voltage ramp.
10 In particular, the patient may report (verbally, by activating a control such as a button, touchscreen, etc.) that the sensation is first felt and/or barely noticeable, and/or when the sensation is strong (e.g., “strong but does not bother me”) and/or very strong (e.g., the “strongest sensation I can tolerate for the treatment period”).

[00020] In general, estimating the peak modulation voltage as a function of the target
15 sensation intensity modulation voltage and therapy ramp-up time may include estimating the peak modulation voltage as a product of a function of the therapy ramp-up time and a function of the target sensation intensity modulation voltage. For example, estimating the peak modulation voltage as a function of the target sensation intensity modulation voltage and therapy ramp-up time may comprise estimating the peak modulation voltage as a square root of a product of the
20 therapy ramp-up time and the target sensation intensity modulation voltage.

[00021] Any of these methods may also include determining a minimum patient-detectable modulation voltage that is specific to the patient from the test voltage ramp and further wherein setting the therapeutic dose comprises using the minimum patient-detectable modulation voltage as a starting voltage for the therapeutic dose. For example, determining the minimum patient-
25 detectable modulation voltage may include receiving patient reported feedback during the application of the test voltage ramp, as mentioned above.

[00022] In general, setting the therapeutic dose may include setting the therapeutic dose in the implanted neuromodulator or a controller in communication with the implanted neuromodulator. Setting the therapeutic dose may also include setting one or more of: the therapeutic dose
30 duration, the therapy ramp-up time to reach the peak modulation voltage, and the sustained peak modulation time. These parameters may be set for the test voltage ramp.

[00023] In general, the applied therapeutic energy may include a high-frequency modulation signal (waveform) that is ramped up to a plateau value. As mentioned above, any of these methods may also include setting the frequency of the high-frequency component of the test
35 voltage ramp applied and setting a frequency of the high-frequency component of the therapeutic

dose to the frequency of the high-frequency component of the test voltage ramp applied. For example, the frequency of the high-frequency component of the test voltage ramp applied may be between 1 kHz and 100 kHz.

5 [00024] Any of these methods may also include setting an alternative therapeutic dose of the neuromodulator implanted into a patient. The alternative therapeutic dose may comprise an alternative peak modulation voltage that is between about 60% and 95% of the peak modulation voltage. The alternative therapy dose may be provided to allow the patient to apply one or the other therapy doses (the therapy dose or the alternative therapy dose) at their preference.

10 [00025] For example, a method of setting a therapeutic dose of a neuromodulator implanted into a patient, wherein the therapeutic dose comprises a therapeutic dose duration including a therapy ramp-up time to reach a peak modulation voltage and a sustained peak modulation time during which the voltage is sustained at the peak modulation voltage, may include: applying a test voltage ramp from the neuromodulator implanted into the patient; determining a minimum patient-detectable modulation voltage that is specific to the patient from the test voltage ramp; 15 determining a target sensation intensity modulation voltage that is specific to the patient from the test voltage ramp; estimating the peak modulation voltage as a product of a function of the target sensation intensity modulation voltage and a function of the therapy ramp-up time to reach the peak modulation voltage; and setting the therapeutic dose using the estimated peak modulation voltage and using the minimum patient-detectable modulation voltage as a starting voltage for 20 the therapeutic dose.

[00026] Also described herein are systems that are configured to implement any of the methods described herein either automatically or semi-automatically. For example, a system may include: an implantable neuromodulator; a controller for controlling the application of a therapeutic dose by the neuromodulator, wherein the therapeutic dose comprises a therapeutic 25 dose duration including a therapy ramp-up time to reach a peak modulation voltage and a sustained peak modulation time during which the voltage is sustained at the peak modulation voltage, the controller comprising one or more processors; memory coupled to the one or more processors, the memory configured to store computer-program instructions, that, when executed by the one or more processors, implement a computer-implemented method, the computer- 30 implemented method comprising: applying a test voltage ramp from the neuromodulator implanted into the patient; determining a target sensation intensity modulation voltage that is specific to the patient from the test voltage ramp; estimating the peak modulation voltage as a function of the target sensation intensity modulation voltage and the therapy ramp-up time to reach the peak modulation voltage; and setting the therapeutic dose using the estimated peak 35 modulation voltage.

[00027] The computer-implemented method may include any of the steps described above, which may be implemented by the controller. For example, when determining a target sensation intensity modulation voltage that is specific to the patient from the test voltage ramp, the controller may prompt the patient or otherwise allow the patient to enter their reported sensation
5 induced by the ongoing modulation.

BRIEF DESCRIPTION OF THE DRAWINGS

[00028] The novel features of the invention are set forth with particularity in the claims that follow. A better understanding of the features and advantages of the present invention will be
10 obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:

[00029] FIG. 1 shows one example of a neuromodulation system (showing a nerve cuff, lead and implantable controller/waveform generator).

15 [00030] FIG. 2 shows an example of the system of FIG. 1 implanted into a patient (also showing a controller (in this example, an external controller) for controlling and applying a therapeutic dose.

[00031] FIG. 3A is an example of a schematic of a voltage profile of a therapeutic dose.

20 [00032] FIG. 3B illustrates examples a schematic of the voltage profiles of two therapeutic doses that may be applied by an implanted neuromodulator as described herein.

[00033] FIG. 3C illustrates another example of a voltage profile of a therapeutic dose.

[00034] FIG. 4 is a flow diagram illustrating one method of setting a therapeutic dose for an implantable neuromodulator as described herein.

25 [00035] FIGS. 5A-5H are tables that may be used to determine a therapeutic dose. FIGS. 5A-5H include test parameter setting (FIG. 5A and 5B), time elapsed and therapy induced sensation described by subject (FIG.5C), initial amplitude based on time when induced sensation was "first felt" (FIG. 5D), look-up tables to determine final amplitude (V_p) based on the strength of the induced sensation (FIG. 5E) and a discounted final amplitude for a second, alternative, dose (FIG. 5F). FIGS. 5G and 5H are tables illustrating test parameters, including the final parameter
30 settings determined from FIGS. 5A-5G.

[00036] FIGS. 6A-6C are tables that may be used in one method for adjusting therapeutic dose.

DETAILED DESCRIPTION

[00037] In general, the methods and apparatuses for performing them described herein allow optimized dose setting of a neuromodulation apparatus so that the therapy dose provided by the neuromodulator maximizes the energy which may enhance the effect of the neuromodulation on the target nerve(s) without irritating or harming the patient. These methods and apparatuses may be generally described for use with an implanted neuromodulator, but may be also or alternatively be used with external neuromodulators or neuromodulators prior to implantation. Further, the examples provided herein are provided in reference to neuromodulatory inhibition by the application of high-frequency neuromodulation, however these methods and apparatuses may also be used with other neurostimulatory regimes including general neuromodulation. Examples of neuromodulator apparatuses and methods that may benefit from these methods and apparatuses may include, for example, spinal cord stimulators (SCS) and any other neuromodulation application that may be improved by the optimization between therapeutic benefit and induced sensation.

[00038] The inventors have generally found that increasing the applied voltage of neuromodulation is beneficial, particularly when sustained at a high voltage (e.g., high peak voltage). However, high voltage neuromodulation applied to a patient's nerve may result in pain and discomfort when the modulation exceeds a threshold voltage during the ramp up to the sustained high voltage. The value of this threshold may vary between patients and also appears to vary based on the recent modulation already experienced by the nerve as well as the modulation parameters (e.g., frequency). In general, a slower ramp up to a peak modulation voltage in a therapeutic dose may result in lower intensities of induced sensation, and therefore correspondingly higher peak modulation voltages. However, it is also beneficial for a therapeutic dose to maintain the peak modulation voltage for as long as possible during the therapeutic dose.

[00039] Described herein are methods of determining a target sensation intensity modulation voltage using a generic test ramp and adapting this target intensity of modulation to determine an optimal peak modulation voltage for neuromodulation.

[00040] These methods and apparatuses may be used with any appropriate neuromodulator. FIG. 1 illustrates one example of an implantable neuromodulator including a nerve cuff 101, a lead 103 connecting the nerve cuff to a controller (e.g., waveform generator, control circuitry, power source, communications circuitry and/or antenna, etc.) 105. Systems including a nerve cuff such as those described herein, may be used, for example, to apply a high frequency nerve block to acutely treat pain, either acute pain or chronic pain (more than 6 months in duration), in humans by blocking nerve conduction on an action potential. Acute treatment may refer to on-

demand treatment with substantially immediate pain relief effect. The nerve cuff may be applied onto a moderate and relatively large diameter nerves such as the sciatic nerve. One therapy involves reversibly blocking peripheral nerves by applying high frequency alternating current directly on a nerve trunk. Specifically, a current ranging from 1 kHz to 100 kHz (e.g., 5 kHz to 50 kHz) may be applied; this may be referred to as a high frequency modulation, compared to a current of less than 1 kHz applied in the conventional electrical modulation described above. Efficacy of the high frequency alternating current therapy in acute non-human animal experiments (frog, cat) has been reported. U.S. Pat. Nos. 7,389,145 and 8,060,208 describe in general this electrical modulation technology.

10 **[00041]** The nerve cuffs may encircle a particular segment of a targeted peripheral nerve, e.g., a sciatic nerve, a tibial nerve, etc. Using an implanted electrode connected to an electrical waveform generator, an electrical waveform may be applied for a time interval, e.g., 10 min (15 min, 20 min, 25 min, 30 min, 35 min, 40 min, etc.), sufficient to effect substantially immediate patient pain relief, e.g., within 10 min, and an extended period of pain relief up to several hours. 15 The current may range, for example, from 4 mApp to 26 mApp.

[00042] The application of 10 kHz alternating current generated by a custom generator via a custom implanted nerve electrode may significantly reduce pain in the majority of patients treated. For example, an implantable electrode operatively connected to an external or implanted waveform generator may be used. The electrode may be a spiral cuff electrode similar to that 20 described in U.S. Pat. No. 4,602,624. The electrode may be implanted in a human mammal on a desired peripheral nerve trunk proximal to the pain source (e.g., a neuroma), such that the cuff encircled the desired peripheral nerve in which the action potential was to be blocked. The cuff inner diameter may range from about 4 mm to about 13 mm. The sciatic nerve is known to have a relatively large nerve trunk; the diameter of the proximal part of the sciatic nerve in a human 25 adult is about 12 mm. In one embodiment, the apparatus and method was used on the sciatic nerve to treat limb pain in above knee amputees. In one embodiment, the apparatus and method was used on the tibial nerve to treat limb pain in below knee amputees.

[00043] For example, FIG. 2 illustrates the use of a system including a cuff electrode applied to the sciatic nerve of an amputee patient. In this example, the amputee 107 has been implanted 30 with a nerve cuff 101 around the sciatic nerve (nerve trunk), and is connected, via a lead 103, to the controller including the waveform generator 105. This procedure may be done, for example, by first dissecting to expose the nerve in an open procedure, then wrapping the nerve with the flexible (self-closing) cuff. Once implanted the controller/waveform generator may be placed in a pocket in the anterolateral abdominal wall, and a tunneling electrode cable may be positioned 35 along the midaxillary line (including transversely across the abdomen) to connect the

controller/waveform generator to the nerve cuff electrode. Once the impedance of the nerve cuff is checked (e.g., by the controller) the incisions may be closed. The incision for implanting the nerve cuff is typically larger than about 1.5 inches (e.g., between 1.5 and 3 inches), so that sufficient visualization and access may be achieved. Once implanted and allowed to heal, the
5 implanted neuromodulator may be set as described herein to provide an optimized therapeutic dose as described herein.

[00044] The system shown in FIG. 2 also includes a controller 131, shown as an external controller that include one or more processors and may be configured to perform the methods described herein. The controller, or a separate device coupled to the controller, may include an
10 input for the user to report the sensation induced by the applied modulation, including the test ramp, as will be described in greater detail below.

[00045] In general a therapeutic dose for a neuromodulator may have at least two portions. FIG. 3A illustrates one example of an exemplary voltage profile of a therapeutic dose. In this example, the first portion of the therapeutic dose is a ramp-up period 303, which has a duration
15 (referred to as a therapy ramp-up time to reach a peak modulation voltage, V_1 in FIG. 3A) of T_{plateau} that is between 10% and 90% of the total duration of the therapeutic dose (T_{duration}). The second portion of the therapeutic dose is a sustained peak modulation time 305 during which the voltage is sustained at the peak modulation voltage (V_1), this may also be referred to as the plateau portion.

[00046] During the ramp-up portion of the therapeutic dose, the neuromodulator may apply an increasing intensity of modulation from the start (time 0, T_0) to the peak modulation voltage (V_1) at time T_{plateau} . In FIG. 3A this ramp period is shown as a linear increase, however it may increase in steps (e.g., incrementally increase following regular interval, such as increasing by
20 0.5 V every 30 seconds, etc.). In practice, the modulation may be applied with a high-frequency component having a frequency of between about 1 kHz and 100 kHz (e.g., 1 kHz and 50kHz, 1 kHz and 40 kHz, 1 kHz and 30 kHz, 1kHz and 25 kHz, about 5 kHz, about 10 kHz, etc.).

[00047] FIG. 3B illustrates another example of a pair of therapeutic dose profiles. In one example 309, a rapid ramp up reaches a first voltage level (V_2), and is held at this first voltage level for the duration of the dose. This first voltage level may result in a first sensation intensity
30 for the patient, including a sensation intensity that is the maximum sensation that can be tolerated for the dose. The second profile 311 shows an example in which an approximately equivalent sensation intensity for the patient may be experienced, but with a much high voltage (V_3) that is reached by ramping up over a longer time period (shown as $T_{1/2}$, approximately half of the duration of the dose, T_{duration}). In this example, although the time at which the modulation
35 applied is at the maximum peak voltage is longer for the first profile, the second profile has a

much higher maximum peak voltage. In practice, once a maximum peak voltage is determined, a dose profile may be set for the neuromodulator by using a starting voltage (which may be determined from the minimum patient-detectable modulation voltage detectable by the patient) the peak modulation voltage (which may be determined as described herein) the ramp-up time to reach the peak modulation voltage, and either or both the total duration of the dose and/or the plateau duration, or equivalent values from which these values may be derived. The ramp-up time to reach the peak modulation voltage may be expressed as a time, or as a rate of voltage increase. The therapeutic dose may also include the waveform parameters to be applied (e.g., pulsed, such as sinusoidal), and the high-frequency component (e.g., between 1 kHz and 100 kHz, between 1 kHz and 50 kHz, e.g., about 5 kHz, about 10 kHz, etc.), etc.

[00048] In general, the maximum peak voltage may be determined empirically for any patient by applying a test ramp. The test ramp is a test voltage ramp from the neuromodulator implanted into the patient. While applying the test ramp, the patient may be interrogated (either manually or automatically) to determine the intensity experienced by the patient from the modulation. In particular, the patient may be interrogated to determine the first point at which the modulation becomes either noticeable or consistently perceived (e.g., a minimum patient-detectable modulation voltage). In some variations, this value may be used as the starting voltage during the therapeutic dose. The patient may also be interrogated to determine the target sensation intensity modulation voltage to be applied during the therapy dose. In some variations, this may be the maximum patient-tolerable modulation voltage.

[00049] The patient may be interrogated by prompting and/or receiving patient self-reported sensations. These sensations may be ranked (e.g., 1, corresponding to “I just started to feel the therapy;” 2, corresponding to “I only notice it when I pay attention to it;” 3, corresponding to “strong sensation but it doesn’t bother me;” 4, corresponding to “strongest sensation that I can tolerate for 15-20 min;” and 5, corresponding to “I cannot tolerate this sensation for longer than a few minutes”). The apparatus may include an input that receives the patient intensity reporting and correlates intensity input to the applied voltage and/or the time during which the intensity was reported (which is equivalent information).

[00050] Alternatively, in some variations the apparatus may interrogate the patient indirectly, by monitoring patient biometric information (heart rate, pulse, blood pressure, ensemble nerve activity, skin conductance, respiration, biomarker, including pain biomarker, levels, etc.) that may also be correlated with this applied ramp to determine a target sensation intensity modulation voltage, including a maximum patient-tolerable modulation voltage.

[00051] Based on the identified voltage of the target sensation intensity from the applied test ramp, the method and/or apparatus may determine a target sensation intensity modulation

voltage that is specific to the patient. This target sensation intensity modulation voltage (e.g., V_s) may then be used to calculate, e.g., estimate, the peak modulation voltage (V_p) in conjunction with the intended therapy ramp-up time to reach this peak modulation voltage (T_p). Although the intended ramp-up time may be set to different values (typically between 10% and 90% of the total duration of the therapeutic dose), it may be set to, for example, half of the duration of the therapeutic dose (e.g., $T_{1/2}$). For example, the peak voltage may be set to be:

$$V_p = \sqrt{(T_p \times V_s)} = \sqrt{(T_p \times T_s \times R_s)} \quad (1)$$

[00052] As mentioned, V_s is the voltage of the target sensation intensity determined by from the test ramp, T_p is the ramp up time to get to the peak voltage, and R_s is the ramp rate used during the test (since $T_s \times R_s$ is equivalent to V_s).

[00053] In some cases, where it is assumed that the duration of a therapeutic dose will be approximately 30 minutes, a 15 minute ramp-up time will result in an approximation for the V_p from the identified V_s of:

$$V_p = 4 * \sqrt{V_s} \quad (2)$$

[00054] An example of this method is provided below, and shown in corresponding FIGS. 5A-6E.

[00055] EXAMPLE

[00056] In one example, a maximum tolerable therapy voltage for each nerve was determined using the method described above. The implanted apparatus was similar to that shown in FIGS. 1 and 2. Patients for which an implantable neuromodulator was implanted were allowed to heal, and then trained to report sensations induced by modulation as:

[00057] First felt – “I just started to feel the therapy”

[00058] Weak – “I only notice it when I pay attention to it”

[00059] Strong – “Strong sensation but it doesn’t bother me”

[00060] Very Strong – “Strongest sensation that I can tolerate for 15-20 min”

[00061] Too Strong – “I cannot tolerate this sensation for longer than a few minutes

[00062] General set (e.g., pre-set) parameters for test as shown in FIG. 5A. FIG. 5B is a table illustrating the test parameter settings for the implanted apparatus. In this device, the two doses (dose 1 and dose 1), and two channels (channel A and channel B) are available. In FIG. 5B, only one (dose 1, channel A) is used (“enabled”). As shown in FIG. 5A, the general parameters include a sinusoidal waveform shape having a frequency of 10 kHz, and an initial amplitude (V_p) or 0 V. The initial ramp duration is intended to be 15 minutes plateau duration is 15 min (so the total dose duration is 30 min).

[00063] The test is started by simultaneously starting a clock and starting dose 1. The time is recorded along with the patient-reported induced sensation strength on NRS (e.g., in this

example, in table 1.2a shown in FIG. 5C) for each sensation level. In this example, this sensation may most likely be a tingle or numbness on the medial side or foot of the phantom limb for these patients. If no sensation is felt in < 5 min, abort test by clicking on “Stop Therapy” button and repeat with a different frequency (e.g., 5 kHz) after a rest period (e.g., 15 min of rest) to allow nerve recovery. Pilot study data indicated that similar therapeutic effects can be achieved at lower amplitudes by using a 5 kHz signal. When subject reports induced sensation as “Too strong”, the therapy may be turned OFF by clicking on “Stop Therapy” button. The time may be recorded (e.g., in Table 1.2a) as well as the subject reported NRS rating of induced sensation

5
10 [00064] Based on the time and therefore the voltage at which the sensation was first felt, a minimum patient-detectable modulation voltage that is specific to the patient from the test voltage ramp may be determined. Table 1.3 (FIG. 5D) provide a simplified look-up table to convert the reported time into the minimum patient-detectable modulation voltage. For example, by identifying an initial amplitude corresponding to this value on Table 1.3, corresponding to “First felt” time (e.g., for a first felt time of 01:18, the value is 1.0 V).

15 [00065] Similarly, the target sensation intensity modulation voltage that is specific to the patient may be determined from the test voltage ramp data. FIGS. 5E and 5F provide look-up tables that may be used to estimate the peak modulation voltage as a function of the target sensation intensity modulation voltage and the therapy ramp-up time to reach the peak modulation voltage, where the therapy ramp-up time is assumed to be 15 minutes (e.g., half of a 30 minute dose). In this example, the final amplitudes for dose may be identified from table 1.4a (FIG. 5E). Alternatively equation (1), above, may be used. In this example, the reported intensity corresponding to “Too Strong” time (e.g., for a “Too Strong” time of 07:35, the indicated value is 11.0 V) may be used to indicate the target sensation intensity modulation voltage.

20 [00066] FIG. 5F and table 1.4b provide a second, scaled peak amplitude that is 0.8x the value determined from Equation 1 and table 1.4a. This second dose may be provided as an alternative dose.

25 [00067] FIGS. 5G and 5H (table 1.1b) illustrate the final parameter settings for the therapeutic dose determined as described above. In this example, the general parameters may be as indicated in FIG. 5G, and the final parameter settings may be entered into the table 1.1b shown in FIG. 5H. For example, the initial amplitude may be entered into the table based on the minimum patient-detectable modulation voltage determined above. The final amplitude identified (e.g., using Table 1.4a and Table 1.4b in FIGS. 5E and 5F) may be included in the final parameters. In

this example, the lockout period is set to 0.5 hours and the frequency is set to about, e.g., 5 kHz, if testing was done at 5 kHz.

5 [00068] When two dose variations are given, as shown, the subject may be instructed to use both dose 1 and dose 2 initially for several days and then pick the one they feel is more effective in pain reduction.

[00069] In some variations, the programming (the dose information) may be set, for example every week for 3-4 weeks following the initial setting and periodically thereafter. This may allow the method and/or apparatus to adjust the final amplitude to maximize therapy voltage within tolerable limits of induced sensation. The method described above may be adjusted based on
10 patient-reported sensation. For example, the final voltage may be adjusted as indicated in FIG. 6A (Table 2.1) and the procedure outlined above may be repeated (e.g., to complete the tables shown in FIGS. 6B and 6C).

[00070] Any of the methods (including user interfaces) described herein may be implemented as software, hardware or firmware, and may be described as a non-transitory computer-readable
15 storage medium storing a set of instructions capable of being executed by a processor (e.g., computer, tablet, smartphone, etc.), that when executed by the processor causes the processor to control perform any of the steps, including but not limited to: displaying, communicating with the user, analyzing, modifying parameters (including timing, frequency, intensity, etc.), determining, alerting, or the like.

20 [00071] When a feature or element is herein referred to as being "on" another feature or element, it can be directly on the other feature or element or intervening features and/or elements may also be present. In contrast, when a feature or element is referred to as being "directly on" another feature or element, there are no intervening features or elements present. It will also be understood that, when a feature or element is referred to as being "connected", "attached" or
25 "coupled" to another feature or element, it can be directly connected, attached or coupled to the other feature or element or intervening features or elements may be present. In contrast, when a feature or element is referred to as being "directly connected", "directly attached" or "directly coupled" to another feature or element, there are no intervening features or elements present. Although described or shown with respect to one embodiment, the features and elements so
30 described or shown can apply to other embodiments. It will also be appreciated by those of skill in the art that references to a structure or feature that is disposed "adjacent" another feature may have portions that overlap or underlie the adjacent feature.

[00072] Terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. For example, as used herein, the singular
35 forms "a", "an" and "the" are intended to include the plural forms as well, unless the context

clearly indicates otherwise. It will be further understood that the terms "comprises" and/or "comprising," when used in this specification, specify the presence of stated features, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, steps, operations, elements, components, and/or groups thereof. As used
5 herein, the term "and/or" includes any and all combinations of one or more of the associated listed items and may be abbreviated as "/".

[00073] Spatially relative terms, such as "under", "below", "lower", "over", "upper" and the like, may be used herein for ease of description to describe one element or feature's relationship to another element(s) or feature(s) as illustrated in the figures. It will be understood that the
10 spatially relative terms are intended to encompass different orientations of the device in use or operation in addition to the orientation depicted in the figures. For example, if a device in the figures is inverted, elements described as "under" or "beneath" other elements or features would then be oriented "over" the other elements or features. Thus, the exemplary term "under" can encompass both an orientation of over and under. The device may be otherwise oriented (rotated
15 90 degrees or at other orientations) and the spatially relative descriptors used herein interpreted accordingly. Similarly, the terms "upwardly", "downwardly", "vertical", "horizontal" and the like are used herein for the purpose of explanation only unless specifically indicated otherwise.

[00074] Although the terms "first" and "second" may be used herein to describe various features/elements (including steps), these features/elements should not be limited by these terms,
20 unless the context indicates otherwise. These terms may be used to distinguish one feature/element from another feature/element. Thus, a first feature/element discussed below could be termed a second feature/element, and similarly, a second feature/element discussed below could be termed a first feature/element without departing from the teachings of the present invention.

[00075] Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising" means various components can be co-jointly employed in the methods and articles (e.g.,
25 compositions and apparatuses including device and methods). For example, the term "comprising" will be understood to imply the inclusion of any stated elements or steps but not
30 the exclusion of any other elements or steps.

[00076] In general, any of the apparatuses and methods described herein should be understood to be inclusive, but all or a sub-set of the components and/or steps may alternatively be exclusive, and may be expressed as "consisting of" or alternatively "consisting essentially of" the various components, steps, sub-components or sub-steps.

[00077] As used herein in the specification and claims, including as used in the examples and unless otherwise expressly specified, all numbers may be read as if prefaced by the word "about" or "approximately," even if the term does not expressly appear. The phrase "about" or "approximately" may be used when describing magnitude and/or position to indicate that the value and/or position described is within a reasonable expected range of values and/or positions. For example, a numeric value may have a value that is +/- 0.1% of the stated value (or range of values), +/- 1% of the stated value (or range of values), +/- 2% of the stated value (or range of values), +/- 5% of the stated value (or range of values), +/- 10% of the stated value (or range of values), etc. Any numerical values given herein should also be understood to include about or approximately that value, unless the context indicates otherwise. For example, if the value "10" is disclosed, then "about 10" is also disclosed. Any numerical range recited herein is intended to include all sub-ranges subsumed therein. It is also understood that when a value is disclosed that "less than or equal to" the value, "greater than or equal to the value" and possible ranges between values are also disclosed, as appropriately understood by the skilled artisan. For example, if the value "X" is disclosed the "less than or equal to X" as well as "greater than or equal to X" (e.g., where X is a numerical value) is also disclosed. It is also understood that the throughout the application, data is provided in a number of different formats, and that this data, represents endpoints and starting points, and ranges for any combination of the data points. For example, if a particular data point "10" and a particular data point "15" are disclosed, it is understood that greater than, greater than or equal to, less than, less than or equal to, and equal to 10 and 15 are considered disclosed as well as between 10 and 15. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.

[00078] Although various illustrative embodiments are described above, any of a number of changes may be made to various embodiments without departing from the scope of the invention as described by the claims. For example, the order in which various described method steps are performed may often be changed in alternative embodiments, and in other alternative embodiments one or more method steps may be skipped altogether. Optional features of various device and system embodiments may be included in some embodiments and not in others.

Therefore, the foregoing description is provided primarily for exemplary purposes and should not be interpreted to limit the scope of the invention as it is set forth in the claims.

[00079] The examples and illustrations included herein show, by way of illustration and not of limitation, specific embodiments in which the subject matter may be practiced. As mentioned, other embodiments may be utilized and derived there from, such that structural and logical substitutions and changes may be made without departing from the scope of this disclosure.

Such embodiments of the inventive subject matter may be referred to herein individually or collectively by the term “invention” merely for convenience and without intending to voluntarily limit the scope of this application to any single invention or inventive concept, if more than one is, in fact, disclosed. Thus, although specific embodiments have been illustrated and described
5 herein, any arrangement calculated to achieve the same purpose may be substituted for the specific embodiments shown. This disclosure is intended to cover any and all adaptations or variations of various embodiments. Combinations of the above embodiments, and other embodiments not specifically described herein, will be apparent to those of skill in the art upon reviewing the above description.

10

CLAIMS

What is claimed is:

1. An method of setting a therapeutic dose of a neuromodulator implanted into a patient,
5 wherein the therapeutic dose comprises a therapeutic dose duration including a therapy ramp-up time to reach a peak modulation voltage and a sustained peak modulation time during which the voltage is sustained at the peak modulation voltage, the method comprising:
applying a test voltage ramp from the neuromodulator implanted into the patient;
determining a target sensation intensity modulation voltage that is specific to the patient
10 from the test voltage ramp;
estimating the peak modulation voltage as a function of the target sensation intensity modulation voltage and the therapy ramp-up time to reach the peak modulation voltage; and
setting the therapeutic dose using the estimated peak modulation voltage.
- 15 2. The method of claim 1, wherein the target sensation intensity modulation voltage is a maximum patient-tolerable modulation voltage
3. The method of claim 1, wherein the therapy ramp-up time to the peak modulation voltage is set to be half of the therapeutic dose duration.
4. The method of claim 1, wherein the therapeutic dose duration is set to be 30 minutes.
- 20 5. The method of claim 1, wherein determining the target sensation intensity modulation voltage comprises determining the voltage of the test voltage ramp being applied when a patient-reported feedback indicating the strongest sensation that the patient can tolerate for a therapeutic dose is received during the application of the test voltage ramp.
6. The method of claim 1, wherein estimating the peak modulation voltage as a function of the
25 target sensation intensity modulation voltage and therapy ramp-up time comprises estimating the peak modulation voltage as a square root of a product of the therapy ramp-up time and the target sensation intensity modulation voltage.
7. The method of claim 1, wherein estimating the peak modulation voltage as a function of the
30 target sensation intensity modulation voltage and therapy ramp-up time comprises estimating the peak modulation voltage as a square root of a product of the therapy ramp-up time and the target sensation intensity modulation voltage.

8. The method of claim 1, further comprising determining a minimum patient-detectable modulation voltage that is specific to the patient from the test voltage ramp and further wherein setting the therapeutic dose comprises using the minimum patient-detectable modulation voltage as a starting voltage for the therapeutic dose.
- 5 9. The method of claim 8, wherein determining the minimum patient-detectable modulation voltage comprises receiving patient reported feedback during the application of the test voltage ramp.
10. The method of claim 1, wherein setting the therapeutic dose comprises setting the therapeutic dose in the implanted neuromodulator or a controller in communication with the implanted neuromodulator.
- 10 11. The method of claim 1, further comprising, prior to setting the therapeutic dose using the estimated peak modulation voltage, setting one or more of: the therapeutic dose duration, the therapy ramp-up time to reach the peak modulation voltage, and the sustained peak modulation time.
- 15 12. The method of claim 1, further comprising setting a high-frequency component of the test voltage ramp applied and setting a high-frequency component of the therapeutic dose to the high-frequency component of the test voltage ramp applied.
13. The method of claim 12, wherein the high-frequency component of the test voltage ramp applied is between 1 kHz and 100 kHz.
- 20 14. The method of claim 1 further comprising setting an alternative therapeutic dose of the neuromodulator implanted into a patient, wherein alternative therapeutic dose comprises an alternative peak modulation voltage that is between about 60% and 95% of the peak modulation voltage.
- 25 15. An method of setting a therapeutic dose of a neuromodulator implanted into a patient, wherein the therapeutic dose comprises a therapeutic dose duration including a therapy ramp-up time to reach a peak modulation voltage and a sustained peak modulation time during which the voltage is sustained at the peak modulation voltage, the method comprising:
applying a test voltage ramp from the neuromodulator implanted into the patient;
determining a minimum patient-detectable modulation voltage that is specific to the
30 patient from the test voltage ramp;

- determining a target sensation intensity modulation voltage that is specific to the patient from the test voltage ramp;
- estimating the peak modulation voltage as a product of a square root of the target sensation intensity modulation voltage and a function of the therapy ramp-up time to reach the peak modulation voltage; and
- 5 setting the therapeutic dose using the estimated peak modulation voltage and using the minimum patient-detectable modulation voltage as a starting voltage for the therapeutic dose.
16. A system comprising:
- 10 an implantable neuromodulator;
- a controller for controlling the application of a therapeutic dose by the neuromodulator, wherein the therapeutic dose comprises a therapeutic dose duration including a therapy ramp-up time to reach a peak modulation voltage and a sustained peak modulation time during which the voltage is sustained at the peak modulation
- 15 voltage, the controller comprising one or more processors;
- memory coupled to the one or more processors, the memory configured to store computer-program instructions, that, when executed by the one or more processors, implement a computer-implemented method, the computer-implemented method comprising:
- 20 applying a test voltage ramp from the neuromodulator implanted into the patient;
- determining a target sensation intensity modulation voltage that is specific to the patient from the test voltage ramp;
- estimating the peak modulation voltage as a function of the target sensation intensity modulation voltage and the therapy ramp-up time to reach the peak modulation
- 25 voltage; and
- setting the therapeutic dose using the estimated peak modulation voltage.
17. The system of claim 16, wherein the target sensation intensity modulation voltage is a maximum patient-tolerable modulation voltage.
18. The system of claim 16, wherein the therapy ramp-up time to the peak modulation voltage is set to be half of the therapeutic dose duration.
- 30 19. The system of claim 16, wherein the therapeutic dose duration is set to be 30 minutes.

20. The system of claim 16, wherein determining the target sensation intensity modulation voltage comprises determining the voltage of the test voltage ramp being applied when a patient-reported feedback indicating the strongest sensation that the patient can tolerate for a therapeutic dose is received during the application of the test voltage ramp.
- 5 21. The system of claim 16, wherein estimating the peak modulation voltage as a function of the target sensation intensity modulation voltage and therapy ramp-up time comprises estimating the peak modulation voltage as a product of a function of the therapy ramp-up time and the square root of the target sensation intensity modulation voltage.
- 10 22. The system of claim 16, wherein estimating the peak modulation voltage as a function of the target sensation intensity modulation voltage and therapy ramp-up time comprises estimating the peak modulation voltage as a square root of a product of the therapy ramp-up time and the target sensation intensity modulation voltage.
- 15 23. The system of claim 16, wherein the computer-implemented method further comprises: determining a minimum patient-detectable modulation voltage that is specific to the patient from the test voltage ramp and further wherein setting the therapeutic dose comprises using the minimum patient-detectable modulation voltage as a starting voltage for the therapeutic dose.
- 20 24. The system of claim 16, wherein determining the minimum patient-detectable simulation voltage comprises receiving patient reported feedback during the application of the test voltage ramp.
- 25 25. The system of claim 16, wherein setting the therapeutic dose comprises setting the therapeutic dose in the implanted neuromodulator or a controller in communication with the implanted neuromodulator.
26. The system of claim 16, wherein the computer-implemented method further comprises, prior to setting the therapeutic dose using the estimated peak modulation voltage, setting one or more of: the therapeutic dose duration, the therapy ramp-up time to reach the peak modulation voltage, and the sustained peak modulation time.
- 30 27. The system of claim 16, wherein the computer-implemented method further comprises setting a high-frequency component of the test voltage ramp applied and setting a high-frequency component of the therapeutic dose to the high-frequency component of the test voltage ramp applied.

28. The system of claim 16, wherein the high-frequency component of the test voltage ramp applied is between 1 kHz and 100 kHz.
29. The system of claim 16, wherein the computer-implemented method further comprises:
setting an alternative therapeutic dose of the neuromodulator implanted into a patient,
5 wherein alternative therapeutic dose comprises an alternative peak modulation voltage that is
between about 60% and 95% of the peak modulation voltage.




FIG. 2




FIG. 1



FIG. 3A




FIG. 3B




FIG. 3C

3 / 8




FIG. 4

General Parameters	
Waveform	Sinusoidal
Frequency	10 kHz
Lockout	OFF
Channel Sequence	A First
Channel Delay	0 min

FIG. 5A

Table 1.1a: Test Parameter Settings

	Dose 1		Dose 2	
Channel A	Enabled	Yes	Enabled	No
	Initial Amplitude (Vp):	0	Initial Amplitude (Vp):	-
	Ramp Duration (min):	15	Ramp Duration (min):	-
	Final Amplitude (Vp):	15	Final Amplitude (Vp):	-
	Plateau Duration (min):	15	Plateau Duration (min):	-
Channel B	Enabled	No	Enabled	No
	Initial Amplitude (Vp):	-	Initial Amplitude (Vp):	-
	Ramp Duration (min):	-	Ramp Duration (min):	-
	Final Amplitude (Vp):	-	Final Amplitude (Vp):	-
	Plateau Duration (min):	-	Plateau Duration (min):	-

FIG. 5B

Table 1.2a: Time elapsed and therapy induced sensation described by subject

Sensation Description	First felt (Abort if Time ≥ 5 min and repeat with 5 kHz)	Strong	Very Strong	Too Strong Turn OFF Therapy!
Time (min : sec)				
Sensation rating on NRS (0-10)				

FIG. 5C

Table 1.3: Initial Amplitude based on time when induced sensation was "First felt"

Initial Amplitude (V _r)		Seconds		
		0-19	20-39	40-59
Minutes	0	0.2	0.3	0.7
	1	1.0	1.3	1.7
	2	2.0	2.3	2.7
	3	3.0	3.3	3.7
	4	4.0	4.3	4.7

FIG. 5D

a. Dose 1

Minutes	Final Amplitude (V _r)	Seconds					
		0-9	10-19	20-29	30-39	40-49	50-59
0	-		1.6	2.3	2.8	3.3	3.7
1		4.0		4.5		5.0	
2		6.0		6.5			
3		7.0		7.5			
4		8.0		8.5			
5		9.0					
6		10.0					
7		11.0					
8		12.0					
9		12.5					
10		13.0					
11		13.5					
12		14.0					
13		14.5					
14		15.0					
15		16.0					

FIG. 5E

b. Dose 2

Minutes	Final Amplitude (V _r)	Seconds					
		0-9	10-19	20-29	30-39	40-49	50-59
0	-		1.3	1.8	2.2	2.6	3.0
1		3.2		3.6		4.0	
2		4.5		5.0			
3		5.5		6.0			
4		6.5		7.0			
5		7.5					
6		8.0					
7		8.5					
8		9.0					
9		9.5					
10		10.5					
11		11.0					
12		11.0					
13		11.5					
14		12.0					
15		13.0					

FIG. 5F

General Parameters	
Waveform	Sinusoidal
Frequency	5 kHz / 10 kHz
Lockout	0.5 Hr
Channel Sequence	A First
Channel Delay	0 min

FIG. 5G

Table 1.1b: Final Parameter Settings

	Dose 1		Dose 2	
Channel A	Enabled	Yes	Enabled	Yes
	Initial Amplitude (Vp):	(from Table 1.3)	Initial Amplitude (Vp):	(from Table 1.3)
	Ramp Duration (min):	15	Ramp Duration (min):	15
	Final Amplitude (Vp):	(from Table 1.4a)	Final Amplitude (Vp):	(from Table 1.4b)
	Plateau Duration (min):	15	Plateau Duration (min):	15
Channel B	Enabled	No	Enabled	No
	Initial Amplitude (Vp):	-	Initial Amplitude (Vp):	-
	Ramp Duration (min):	-	Ramp Duration (min):	-
	Final Amplitude (Vp):	-	Final Amplitude (Vp):	-
	Plateau Duration (min):	-	Plateau Duration (min):	-

FIG. 5H

Table 2.1: Final Amplitude adjustment based on induced sensation during test

Sensation by D1	Weak	Strong	Very Strong	Too Strong
Adjustment	New = Current * 1.2 [*]	New = Current	New = Current * 0.9 [*]	New = Current * 0.8 [*]

^{*} Suggested factor, actual value to be determined with clinical experience and subject feedback

FIG. 6A

General Parameters	
Waveform	Sinusoidal
Frequency	5 kHz / 10 kHz
Lockout	0.5 Hr
Channel Sequence:	A First
Channel Delay	0 min

FIG. 6B

		Dose 1		Dose 2	
Channel A	Enabled	Yes	Enabled	Yes	
	Initial Amplitude (Vp):	No change	Initial Amplitude (Vp):	Copy from D1	
	Ramp Duration (min):	15	Ramp Duration (min):	15	
	Final Amplitude (Vp):	New Value per Step 5	Final Amplitude (Vp):	D1 * 0.8 [*]	
	Plateau Duration (min):	15	Plateau Duration (min):	15	
Channel B	Enabled	No	Enabled	No	
	Initial Amplitude (Vp):	-	Initial Amplitude (Vp):	-	
	Ramp Duration (min):	-	Ramp Duration (min):	-	
	Final Amplitude (Vp):	-	Final Amplitude (Vp):	-	
	Plateau Duration (min):	-	Plateau Duration (min):	-	

FIG. 6C

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 19/25707

A. CLASSIFICATION OF SUBJECT MATTER IPC(8) - A61N 1/08, A61N 1/18, A61N 1/20, A61N 1/36 (2019.01) CPC - A61N 1/08, A61N 1/36021, A61N 1/36128		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
See Search History Document		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
See Search History Document		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
See Search History Document		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2017/0333701 A1 (GREATBATCH LTD) 23 November 2017 (23.11.2017), fig 2, 7; para [0059], [0094]-[0095], [0235], [0320], [0324]-[0330], [0332], [0326], [0334]	1, 2, 5, 8-11, 14, 16, 17, 20, 23-26, 29
X --- A	US 2013/0289667 A1 (WACNIK et al.) 31 October 2013 (31.10.2013), fig 1, 3, 5A, 9A; para [0004], [0033], [0074], [0076], [0095], [0124]-[0126],	1, 3, 4, 12-13, 16, 18, 19, 27, 28 ----- 6, 7, 15, 21, 22
X --- A	US 2010/0168820 A1 (MANIAK et al.) 01 July 2010 (01.07.2010), para [0005], [0059], [0062], [0077], [0086], [0101], [0115]	1, 16 ----- 6-7, 15, 21-22
A	US 2017/0348532 A1 (BOSTON SCIENTIFIC NEUROMODULATION CORPORATION) 07 December 2017 (07.12.2017), entire document	1-29
A	US 2010/0121408 A1 (IMRAN et al.) 13 May 2010 (13.05.2010), entire document	1-29
A	US 2006/0270944 A1 (KING) 30 November 2006 (30.11.2006), entire document	1-29
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
29 May 2019		24 JUN 2019
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450 Facsimile No. 571-273-8300		Authorized officer: Lee W. Young PCT Helpdesk: 571-272-4300 PCT OSP: 571-272-7774